Status:

COMPLETED

Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer

Lead Sponsor:

Roswell Park Cancer Institute

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Prostate Cancer

Eligibility:

MALE

Phase:

PHASE1

Brief Summary

RATIONALE: The use of nutritional supplements, such as selenium, may stop prostate cancer from growing. Internal radiation, such as brachytherapy, uses radioactive material placed directly into or nea...

Detailed Description

OBJECTIVES: Primary * Compare the effects of selenium vs placebo on tissue biomarkers of prostate cancer susceptibility, using tissue samples from biopsies before and after treatment, in patients un...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically confirmed adenocarcinoma of the prostate
  • Must have undergone ≥ a sextant biopsy
  • Clinical stage T1a-T2a disease
  • Gleason score \< 8
  • Prostate-specific antigen \< 20 ng/mL
  • PATIENT CHARACTERISTICS:
  • Age
  • Not specified
  • Performance status
  • Not specified
  • Life expectancy
  • More than 5 years
  • Hematopoietic
  • Not specified
  • Hepatic
  • Not specified
  • Renal
  • Not specified
  • Other
  • No other prior malignancy except nonmelanoma skin cancer
  • PRIOR CONCURRENT THERAPY:
  • Biologic therapy
  • Not specified
  • Chemotherapy
  • Not specified
  • Endocrine therapy
  • No prior hormonal therapy
  • Radiotherapy
  • No prior radiotherapy
  • Surgery
  • Not specified
  • Other
  • More than 30 days since prior and no concurrent participation in another clinical trial involving a medical, surgical, nutritional, or lifestyle intervention (e.g., dietary modification or exercise)
  • No selenium at doses \> 50 mcg/day as a dietary supplement, including multivitamin supplements

Exclusion

    Key Trial Info

    Start Date :

    March 1 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    October 1 2008

    Estimated Enrollment :

    18 Patients enrolled

    Trial Details

    Trial ID

    NCT00217516

    Start Date

    March 1 2005

    End Date

    October 1 2008

    Last Update

    February 9 2012

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Roswell Park Cancer Institute

    Buffalo, New York, United States, 14263-0001